Founded Year
2011Stage
Series A - IV | AliveTotal Raised
$5.55MLast Raised
$1.4M | 2 yrs agoAbout AgilVax
Agilvax is a biotechnology company employing a vaccine discovery platform to develop safe and efficacious vaccines for infectious diseases and chronic conditions. The platform is based on virus-like particles (VLP) derived from RNA bacteriophages engineered to incorporate vaccine components necessary for the rapid identification of successful candidates.
AgilVax Headquarter Location
5901 Indian School Road NE
Albuquerque, New Mexico, 87110,
United States
505-200-9541
Expert Collections containing AgilVax
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
AgilVax is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
838 items
AgilVax Patents
AgilVax has filed 3 patents.
The 3 most popular patent topics include:
- Clusters of differentiation
- Monoclonal antibodies
- Transcription factors
Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
4/30/2018 | 7/13/2021 | Monoclonal antibodies, Clusters of differentiation, Experimental cancer drugs, Immune system, Transcription factors | Grant |
Application Date | 4/30/2018 |
---|---|
Grant Date | 7/13/2021 |
Title | |
Related Topics | Monoclonal antibodies, Clusters of differentiation, Experimental cancer drugs, Immune system, Transcription factors |
Status | Grant |
Latest AgilVax News
Aug 18, 2020
AgilVax Progress Triggers $1.2 Million SBIR Fast-Track Grant to Advance Antibody-Based Therapy Drug Genius Staff Writer ALBUQUERQUE, N.M.–(BUSINESS WIRE)– AgilVax, Inc ., a biopharmaceutical company that discovers and develops targeted antibody-based therapeutics to treat multiple types of cancer, announced today that the company has triggered Phase II funding worth $1.2 million from its Fast Track Small Business Innovation Research (SBIR) grant awarded by the National Cancer Institute (NCI). The funding will be used to conduct a preclinical efficacy study, manufacturing stability studies and a nonclinical toxicology study for AX09, a virus-like-particle (VLP) therapeutic vaccine. AgilVax successfully achieved its goals from the earlier phases allowing the final portion of the grant to be awarded. AgilVax has three development programs targeting xCT, a cystine-glutamate antiporter: (1) an antibody-drug conjugate (xCT-mAb-ADC), (2), a conjugated radiopharmaceutical and (3) AX09. Oxidative stress leads to enhanced induction of xCT, which regulates cysteine intake, stimulates the conversion of cysteine and subsequent glutathione (GSH) synthesis. xCT expression is low in normal cells but elevated in numerous cancer types corresponding to increases in intracellular reactive oxygen species (ROS). Numerous cancer types are highly resistant to traditional therapies due to oxidative stress induced by cancer cell metabolism. “We are delighted to receive this grant award from the National Cancer Institute to advance the development of our antibody-based therapeutic program,” said Joseph Patti, Ph.D., president and chief executive officer of Agilvax and the Principal Investigator of the award. “Targeting redox-sensitive pathways and a protein that is upregulated in tumors that possess NFR2/KEAP1 or KRAS mutations, offers great promise for cancer therapy and AgilVax is poised to establish a new class of treatment for tough to treat cancers.” About AgilVax AgilVax discovers and develops antibody-based therapeutics for the treatment of various cancers targeting xCT (SLC7A11), a cystine-glutamate antiporter. xCT is over expressed on many different tumor types including breast, colorectal, lung, pancreatic, and hepatocellular cancers. The Company has headquarters in Albuquerque, New Mexico and labs at JLABS @ TMC in Houston, Texas. Contacts
When was AgilVax founded?
AgilVax was founded in 2011.
Where is AgilVax's headquarters?
AgilVax's headquarters is located at 5901 Indian School Road NE, Albuquerque.
What is AgilVax's latest funding round?
AgilVax's latest funding round is Series A - IV.
How much did AgilVax raise?
AgilVax raised a total of $5.55M.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.